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Introduction
Heart transplantation remains a gold standard of treat-
ment for patients with end-stage heart disease. With
the evolution of potent immunosuppressive agents
and post-transplant management, the survival rate of
the patient and graft survival has improved signifi-
cantly. Thus, long-term complications have become
an issue of concern. One of the complications is post-
transplant malignancy. According to the registry of
the Internal Society for Heart and Lung Transplanta-
tion (ISHLT) in 2008,1 the cumulative prevalence 
of malignancy in heart transplantation recipients at 
1 year is 2.9%, and at 10 years is 31.9%. The most
commonly reported tumors are skin cancer and post-
transplant lymphoproliferative disorder. The aim of
this study was to investigate the incidence and types
of malignancies in heart transplant recipients at our
institute.
Methods
Patient population
From January 1987 to December 2008, a total of 
78 patients received heart transplantation at our insti-
tute. Patients who died within 1 month after trans-
plantation were excluded from this study. A total of
66 patients were enrolled. Eight patients who devel-
oped malignancies were identified. Their medical re-
cords were reviewed and patient data, including cancer
type, treatment modality, and survival, were collected.
Immunosuppression
All patients were treated with standard calcineurin
inhibitor-based triple immunosuppressive agent ther-
apy. In the early days, we used azathioprine for in-
duction therapy. After 1999, rabbit antithymocyte
globulins (RATG) replaced it. RATG 0.75–2.0 mg/
kg was given 1 hour before the operation, and the
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infusion was pretreated with the administration of
5 mg chlorpheniramine and 100 mg hydrocortisone.
Then, 500 mg methylprednisolone was infused dur-
ing release of aortic cross-clamp, followed by methyl-
prednisolone 125 mg, 62.5 mg, and 31.25 mg every 8
hours for the 1st, 2nd and 3rd postoperative days,
respectively. After transplantation, RATG at a dose of
1.5–4.0 mg/kg/day was administered for 3 days. Oral
prednisolone (0.5 mg/kg/day tapered to 0.1 mg/kg/
day), cyclosporine and azathioprine were given after
the patient resumed enteral feeding. After 1999, my-
cophenolate mofetil gradually replaced azathioprine,
and tacrolimus replaced cyclosporine as first-line im-
munosuppressive agents for our heart transplant re-
cipients. Tacrolimus dose was adjusted according to the
serum trough level. In most patients, it was maintained
between 5 and 15 ng/mL.
Results
Eight patients (2 pediatric, 6 adult) developed malig-
nancies after heart transplantation, with a prevalence
of 12.1%, at our institute. Patient characteristics at the
time of diagnosis of malignancy, clinical findings and
treatment modalities are listed in Table 1. The me-
dian age at diagnosis was 57.5 years (range, 6–68 years).
Among the 6 adult patients, the median age at diag-
nosis was 63 years (range, 37–68 years). The median
time from transplantation to the diagnosis of malig-
nancy was 12 months (range, 7–106 months).
Five patients were diagnosed to have post-
transplant lymphoproliferative diseases (PTLD). One
patient developed PTLD at 106 months after trans-
plantation, and another patient after 13 months. Oth-
ers were diagnosed with early PTLD (< 1 year). The
clinical symptoms varied, and included anemia and
tarry stool passage, neck lymphadenopathy, bloody
stool passage, and shortness of breath. Diagnosis was
made via imaging studies and subsequent tissue bio-
psy. Monomorphic diffuse large B-cell lymphoma was
the most common subtype. All these patients received
immunosuppression reduction as their first-line treat-
ment. Three of them achieved complete remission, 
1 had partial remission, and another died of multiple
organ failure 3 weeks after the diagnosis of PTLD.
A 58-year-old male patient experienced frequency
and nocturia 5–6 times 11 months after transplanta-
tion. Digital rectal examination revealed induration 
of both lobes of the prostate, and there was elevated
prostate-specific antigen level. Transrectal ultrasound
biopsy showed adenocarcinoma of the prostate, 
Gleason 4+3. Whole body bone scan showed no
metastasis. Radical retropubic prostatectomy was per-
formed smoothly, after which the patient was in stable
condition with normal prostate-specific antigen level.
Another 68-year-old male was accidentally found
to have an ill-defined nodule in the left upper lobe 
of his lungs on chest X-ray 3 years after transplanta-
tion. Chest computed tomography (CT) revealed a
0.8-cm soft tissue nodule over the left upper lobe
without calcification. Another pleura-based soft tissue
density at the left lower lobe was also found. A chest
surgeon performed wedge resection of the left upper
lobe nodule and resection of the involved left 4th and
5th ribs. The pathological report was squamous cell car-
cinoma (SCC), pT3N0M0, stage IIb. The patient re-
covered uneventfully, and follow-up chest CT performed
6 months later showed no evidence of recurrence.
The third patient, a 67-year-old male, was acci-
dentally found to have 2 soft tissue masses in his left
cheek and sternal notch 3 years after transplantation.
Incisional biopsy of the left cheek mass was performed
by a plastic surgeon, and the pathological report re-
vealed SCC. Thus, wide excision of both masses with
a 0.5-cm safe margin was done. The pathological re-
ports all showed SCC. Now, the patient is in stable
condition.
Discussion
With the improvement in graft and patient survival,
long-term complications such as coronary allograft
vasculopathy and post-transplant malignancy have be-
come significantly challenging. Penn and Starzl2 first
described the association between cancer and post-
transplant immunosuppression in 1972. El-Hamamsy
et al3 reported a 21% incidence of malignancy in 207
heart transplant recipients with a mean follow-up of
99 ± 57 months. In the series of O’Neill et al,4 18% of
heart transplant patients developed post-transplant
malignancy at any time during the follow-up period,
and 14% developed malignancy within the first 5 years
post-transplant. Roithmaier et al5 reported an 11.27%
incidence of post-transplant malignancy in heart and/or
lung transplant recipients, and a 7.1-fold increase in
incidence compared with the non-transplant popula-
tion. An overall incidence of 14.4% among Spanish
heart transplant patients with a median follow-up
time of 5.2 years was reported by Crespo-Leiro et al.6
The incidence of all-cause post-transplant neo-
plasm in our series (12.1%) is similar to the above data.
It is also similar to the 15.1% incidence among 5-year
survivors in the 2008 ISHLT Registry report.1 Hsu
et al7 reported a lower incidence of post-transplant
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neoplastic disease in Chinese heart transplant recipients.
The cumulative incidence of malignancy was 2.1% at
1 year, 3.6% at 5 years, and 10.1% at 10 years after
transplantation. No skin cancer or Kaposi’s sarcoma
was reported in that series.
Skin cancer is the most common malignancy in
heart transplant recipients, comprising about 42–50%
in recent studies in the Western world.3,4,7 SCC is the
most common form, occurring 65–250 times as fre-
quently as in the general population, and basal cell
carcinoma occurs 10 times as frequently.8 The patho-
genesis of skin carcinoma is multifactorial. Ultraviolet
radiation appears to be the most important cause, since
the highest incidence of skin cancer is in countries
with the highest sun exposure.9 Hsu et al attributed
the low incidence of post-transplant malignancy in
Chinese heart transplantation recipients to a relative
paucity of Kaposi’s sarcoma and skin cancer.7 In our
series, the finding was proven again. Only 1 SCC over
the left cheek and anterior chest was diagnosed among
the 8 patients with post-transplant malignancies.
PTLD is a well-known complication of transplan-
tation due to the use of potent immunosuppressive
agents. Epstein-Barr virus (EBV) is strongly associ-
ated with PTLD. EBV is a herpes virus that infects
more than 90% of the adult population, and causes
self-limiting illness in childhood. It is believed that
the transformation of EBV-infected B lymphocytes
due to suppression of cytotoxic T cell functions al-
lows uncontrolled proliferation and eventual malig-
nant change.10 However, PTLD is diagnosed in the
absence of EBV in about 10% of cases, which have
increased 10-fold since 1991.11 According to the World
Heath Organization classification, PTLD is divided into
3 categories: early lesions, polymorphic PTLD, and
monomorphic PTLD. Pre-transplant EBV seronegativ-
ity and subsequent conversion after transplantation is
a significant risk factor for the development of PTLD.
Table 1. Patient characteristics
Patient
Age
Organ 
Induction Immuno-
Median Median Median 
Malignancy
(yr)/Sex
transplanted 
therapy suppressive agents
tacrolimus WBC CD4 
type
(reason) level* (ng/mL) count* count*
1 56/M Heart/kidney Azathioprine + Tacrolimus + MMF 12.6 4,800 183 PTLD
(DCM/ESRD) methylprednisolone
2 68/M Heart (ICM) Azathioprine + Tacrolimus + MMF + 7.3 5,714 146 PTLD
methylprednisolone prednisolone
3 59/M Heart (ICM) RATG+methylprednisolone Tacrolimus + 5.2 3,863 387 Prostate cancer
mycophenolic acid
4 6/M Heart (DCM) RATG+methylprednisolone Tacrolimus + mycophenolic 10.3 4,471 376 PTLD
acid + prednisolone
5 6/M Heart RATG+methylprednisolone Tacrolimus + 7.3 8,187 759 PTLD
(severe MR + DCM) mycophenolic acid +
prednisolone
6 68/M Heart (ICM) RATG+methylprednisolone Tacrolimus + MMF 6.7 3,700 194 Lung 
cancer
7 37/M Heart Azathioprine + Tacrolimus + MMF 3.4 5,533 660 PTLD
(ECM + AMI) methylprednisolone
8 67/M Heart (DCM) RATG+methylprednisolone Tacrolimus + MMF + 6.6 7,630 278 Skin
prednisolone
*6-month period before the diagnosis of malignancy; †EBV serum marker (immunofluorescent antibody to viral capsid antigen [VCA]); ‡at the time of diagnosis of malignancy; 
cardiomyopathy; AMI = acute myocardial infarction; RATG = rabbit antithymocyte globulin; MMF = mycophenolate mofetil; PTLD = post-transplant lymphoproliferative disease; 
Barr virus; HTx = heart transplantation; CR = complete remission; MOF = multiple organ failure; PR = partial remission.
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So, young age, especially < 5 years, is a risk factor for
the development of PTLD.12 Our 2 pediatric heart
transplant recipients developed PTLD within 1 year
postoperatively. One of them had extremely high EBV
viral load (9.3 × 105 copies/μg DNA). We assumed
that his PTLD was induced by high EBV viral load.
Most PTLD in cardiac recipients occurred in the
1st year after transplantation,13 as seen in our patients.
The incidence of developing PTLD following a solid
organ transplantation is the highest in intestinal
(31%), lung (3.8–11.7%) and liver (6.8–13.1%) trans-
plants, with the lowest risk in kidney transplant recip-
ients (1.2–9.0%).13 The incidence of PTLD in heart
transplantation patients is about 1.5–11.4%, which is
higher than many other types of allograft.14 However,
as can be seen in the report of Hsu et al7 and our
study, PTLD comprised 62.5% and 66.7%, respec-
tively, of post-transplant malignancies in the Chinese
population. Hoshida et al15 reported that the most
common cancer after kidney transplantation in Japan
was renal cancer (32.6%), followed by gastric cancer
(13.0%), malignant lymphoma (10.9%), and uterine
cancer (8.7%). The distribution of post-transplant
malignancies is different in Western and other Asian
countries.
In our series, only 3 different types of solid organ
malignancies were diagnosed after heart transplan-
tation. Due to the small sample size, it is difficult 
to assess if they were related to immunosuppressive
therapy. However, considering their age, immuno-
suppressive dosage and CD4 count, we believe that
these 3 solid organ malignancies were just incidental
occurrences.
Of the 6 adult patients, 1 developed PTLD 106
months after transplantation. Recent studies have dem-
onstrated that late-onset PTLD is frequently mon-
oclonal neoplasms, usually falling into subtypes 
of non-Hodgkin’s lymphoma, lacks EBV genome 
EBV serum EBV serum 
marker† pre-HTx marker post-HTx‡
Diagnosis after 
Location Histology IgG IgM IgG IgM
Initial
Response
Current
transplant
treatment condition§
(mo)
13 Mass at Plasma cell & 1:160 < 1:10 NA NA Immunosuppression CR Died due 
allograft kidney lymphocyte reduction to acute 
rejection 5.5 yr 
after HTx
7 Gastric M-DLBCL 1:640 < 1:10 1:160 < 1:10 Immunosuppression Died due to Died due to 
lymphoma & reduction MOF PTLD-related MOF 
pericardial mass 8 mo after HTx
11 Right lobe of Adeno- 1:40 < 1:10 NA NA Radical retropubic Stable Stable 2.5 yr 
prostate carcinoma prostatectomy after HTx
8 LAP at neck, occipital M-DLBCL < 1:40 < 1:10 1:160 < 1:10 Immunosuppression PR Stable 1 yr 
area, mediastinum, reduction after HTx
retropharyngeal 
space, spleen
11 Colonic M-DLBCL < 1:10 < 1:10 1:640 < 1:10 Immunosuppression CR Stable 1.5 yr 
lymphoma reduction after HTx
35 LUL, ribs SCC 1:160 < 1:10 NA NA LUL wedge Stable Stable 3.5 yr 
resection + after HTx
rib resection
106 LAP at axillary region, NA NA 1:10 1:320 < 1:10 Immunosuppression CR Stable 10 yr 
mediastinum, mes- reduction after HTx
entery,retroperitoneum
38 Mass lesion at SCC 1:40 < 1:10 NA NA Wide excision Stable Stable 4.3 yr 
left cheek & after HTx
sternal notch
§till December 2008. DCM = dilated cardiomyopathy; ESRD = end-stage renal disease; ICM = ischemic cardiomyopathy; MR = mitral regurgitation; ECM = eosinophilic 
LAP = lymphadenopathy; LUL = left upper lobe; M-DLBCL = monomorphic diffuse large B-cell lymphoma; SCC = squamous cell carcinoma; NA = not available; EBV = Epstein-
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sequences, responds poorly to reduction or discontin-
uation of immunosuppression, and is generally believed
to have poorer outcome compared to early-onset
PTLD.13,16,17 However, 8 months after immunosup-
pression reduction, the patient in this study achieved
complete remission of his PTLD. Further investigation
is warranted for the treatment modalities of Chinese
PTLD patients.
Among our heart transplant recipients, 30 patients
received cyclosporine (45.5%) as their immunosup-
pressive agent, and none of them developed post-
transplant malignancy. Thirty-six (54.5%) patients were
maintained on tacrolimus and 8 (22.2%) of them de-
veloped post-transplant malignancy (p = 0.006). The
more intense the immunosuppression used to prevent
and treat rejection, the higher the incidence of ad-
verse effects and the risk of post-transplant malig-
nancy in heart transplant recipients.18
Cyclosporine was associated with higher incidence
of lymphoma and Kaposi’s sarcoma, but there has
been no convincing evidence that cyclosporine in-
creased the risk of tumors as compared with other
immunosuppressive regimens, in particular conven-
tional azathioprine-based regimens.19,20 Several stud-
ies have even suggested that cyclosporine might
produce a lower incidence of cancers.21,22 A recent 
in vitro and in vivo study indicated that cyclosporine
might promote tumor growth by a nonimmune mech-
anism that would act on the tumor itself by produc-
tion of transforming growth factor-β.23 The clinical
relevance of these rather provocative data awaits fur-
ther careful clinical confirmation.
Tacrolimus has similar immunosuppressive prop-
erties and is more potent than cyclosporine. Penn in
2000 also reported a similar incidence and pathologi-
cal features of tacrolimus-induced post-transplant can-
cers to those observed with other immunosuppressive
agents, in particular cyclosporine.24 A comparative
study failed to identify significant differences between
tacrolimus-based and cyclosporine-based regimens.25
Whether or not a specific immunosuppressive drug
or regimen is more strongly associated with the risk 
of cancer remains controversial, because of the fre-
quently used combination regimens. In our series,
although the use of tacrolimus carried a significantly
higher risk of post-transplant malignancy, the number
of cases was still very small. However, we may try to
shift tacrolimus to cyclosporine instead of immuno-
suppression reduction in the PTLD group to see if
disease remission can be achieved.
Since half of the 8 patients developed malignancy
within 1 year of transplantation, especially those with
PTLD, we recommend that chest and abdominal CT
or magnetic resonance imaging be performed every 
6 months in the 1st postoperative year, followed by
every 1 year.
In conclusion, the long-term outcome of heart
transplantation is strongly affected by the occurrence
of malignancy in immunosuppressed transplant recip-
ients. The incidence of post-transplant malignancy in
the Chinese population is similar to that in Western
countries, but the types of malignancies are different.
PTLD is the most common malignancy and responds
well to immunosuppression reduction. Since post-
transplant malignancy is commonly seen after heart
transplantation, routine screening for malignancy is
mandatory.
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